Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

February 10, 2025

To

BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

Scrip Code: 524558

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter and nine months ended December 31, 2024.

The Press Release is also being uploaded on the website of the Company at www.neulandlabs.com

This is for your information and records.

Yours sincerely,
For **Neuland Laboratories Limited**

SARADA BHAMIDIPATI
Digitally signed by SARADA BHAMIDIPATI
Date: 2025.02.10 16:31:20 +05'30'

Sarada Bhamidipati
Company Secretary

Encl: As above

Neuland Q3FY25 Total income at Rs.401.9 crore; EBITDA at Rs.90.3 crore

Hyderabad, India, February 10, 2025 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the third quarter & nine months ended December 31st, 2024.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *"We saw marginal topline growth this quarter as compared to Q3FY24. Nevertheless, these results align with our initial outlook at the start of the year regarding our expectations for FY25. We are steadily advancing our strategic initiatives and remain optimistic about achieving sustainable long-term growth through acquiring new customers, enhancing our expertise, expanding our capacity flexibly, and refining our processes."*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added *"This quarter's revenues were driven by several important molecules in the commercial CMS and GDS segments. We expect the recently commercialized molecules to scale even as we are on track to enhance our manufacturing capacity. There is good traction from our existing customers reverting for multiple projects as well as fresh interest from a range of new customers. We are seeing increased interest in peptides leading to our recent decision to invest in a larger capacity. Overall, we are confident on the business momentum for the medium as well as long term.*"

Financial Summary

Rs. crore

Particulars	Q3FY25	Q3FY24	YoY Growth (%)	Q2FY25	QoQ Growth (%)	9MFY25	9MFY24	YoY Growth (%)
Total Income	401.9	394.9	1.8%	315.2	27.5%	1,161.5	1,180.8	-1.6%
EBITDA	90.3	122.7	-26.4%	65.7	37.5%	284.6	362.3	-21.5%
EBITDA margin (%)	*22.5%*	*31.1%*	*-860 bps*	*20.8%*	*170 bps*	*24.5%*	*30.7%*	*-620 bps*
Exceptional Item*	55.8	-	-	-	-	76.4	-	-
PAT*	101.4	80.7	25.6%	32.0	217.3%	231.7	232.0	-0.1%
PAT margin (%)	*25.2%*	*20.4%*	*480 bps*	*10.1%*	*1510 bps*	*19.9%*	*19.6%*	*30 bps*
EPS (Basic) Rs.	79.0	62.9	25.6%	24.9	217.3%	180.6	180.8	-0.1%

*Q3FY25 and 9MFY25 Includes exceptional item of sale of investment property of Rs. 55.8 crores and Rs. 76.4 crores respectively.

Q3 FY25 Earnings Call

The company will conduct a one-hour Earnings call at **16:00 hrs. IST** on **Tuesday, February 11, 2025** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

Diamond Pass Registration Link

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed over 980+ Regulatory filings in the US (70 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland
Tel: +91 40 6761 1600
Email: ir@neulandlabs.com
Ravi Udeshi / Minakshi Machutre
EY IR
Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com